There’s a dangerous misconception inside biotech leadership teams:
That a breach begins when it’s discovered. It doesn’t.
By the time your team identifies suspicious activity, the attacker has already spent weeks or months inside your environment. Learning. Observing. Positioning. Planning…worst, stealing IP.
At Single Point of Contact, we’ve seen firsthand how this gap between intrusion and detection becomes the most expensive window in cybersecurity.
And biotech firms, in particular, are paying for it.
The Reality of Detection Timelines
Let’s strip this down to facts.
In modern enterprise environments:
- Average detection time often exceeds 200 days
- Sophisticated attacks remain hidden even longer
- Early-stage compromises frequently go completely unnoticed
That means attackers are not rushing. They are operating with patience because they know most environments are not actively looking for them.
What Happens During Those 200 Days
Executives often ask, “What could someone really do without being detected?”
The better question is: What can’t they do?
Within that window, attackers can:
- Access and copy proprietary research data
- Escalate privileges across systems
- Monitor communications between scientists and leadership
- Identify acquisition targets or partnership strategies
- Plant persistence mechanisms for long-term access
And they don’t need to act loudly. In fact, the most successful breaches are the quiet ones that blend into normal activity.
Why Biotech Is Uniquely Exposed
Biotech environments are inherently complex:
- Distributed research teams
- Cloud-based collaboration platforms
- Third-party vendors and CROs
- High-value intellectual property
This creates what attackers look for:
Surface area without centralized visibility. And when visibility is fragmented, detection slows. When detection slows, exposure grows.
The Executive Blind Spot
Here’s where I’m going to challenge leadership directly.
Many biotech firms believe they are protected because:
- They passed a compliance audit
- They have endpoint security tools deployed
- They rely on internal IT teams to manage alerts
But none of these guarantee timely detection.
Compliance frameworks define minimum standards, not active defense.
Tools generate data, but do not interpret it in real time.
And internal teams, no matter how capable, are rarely staffed for 24×7 threat monitoring.
So the question becomes:
Are you confident in your defenses or are you assuming visibility you don’t actually have?
The Business Impact of Late Detection
Let’s connect detection time to outcomes because that’s where decisions are made.
Delayed detection can lead to:
- Intellectual property loss before patent filing
- Regulatory penalties tied to delayed breach disclosure
- Erosion of investor confidence during funding rounds
- Operational disruption at critical trial phases
- Long-term brand damage within the scientific community
This is not just cybersecurity. This is enterprise risk management.
What Needs to Change
Biotech firms don’t need more alerts.
They need clarity and speed.
That requires:
- 24×7 security monitoring across all environments
- Correlation of activity across endpoints, users, and data flows
- Rapid triage of anomalies before escalation
- A shift from reactive IT support to proactive threat detection
Because the longer an attacker remains undetected, the more control they gain.
And control, in this context, translates directly to business impact.
Final Word
You cannot eliminate every threat.
But you can control how long it remains inside your environment.
And that decision whether intentional or not belongs to leadership.
At Single Point of Contact, we work with biotech organizations that have made that decision consciously. They’ve moved from assuming security…to verifying visibility in real time.
Because in this industry, time is not just money.
It’s research.
It’s innovation.
It’s competitive advantage.
And if a breach is discovered after 200 days, the real question isn’t what was taken.
It’s what was lost before you ever knew to look.
About Single Point of Contact
Single Point of Contact is an experienced MSP in the biotech industry and is a valuable partner, providing specialized knowledge in implementing robust backup strategies and ensuring network security and stability. With deep understanding of regulatory requirements such as HIPAA and FDA’s 21 CFR Part 11, Single Point of Contact safeguards sensitive research data, clinical trial information, and intellectual property. They offer tailored solutions, including automated backups, real-time monitoring, and disaster recovery plans, minimizing downtime and data loss. By managing security protocols, they protect against cyber threats, allowing biotech companies to focus on innovation while ensuring compliance and uninterrupted operations. This expertise enhances productivity and reduces risk. Contact us today to discover more about how we can help your biotech firm with DR, backup and security.
